profit from every $100 of sales.
$0$100
Kalaris Therapeutics
$1.58-5.12% today
-70.5% in 1 year
1-year low $1.581-year high $10.98
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Kalaris Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$43.4 million of profit last year.
SalesProfit
Kalaris Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kalaris Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Kalaris Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -14 | -13 | -52 | -46 | |
| -15 | -14 | -66 | -42 | |
| -15 | -15 | -69 | -43 | |
| -11.64 | -11.05 | -3.70 | -2.85 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4 | 3 | 6 | 122 |
| Cash | 3 | 3 | 2 | 98 |
| Total debt | 3 | – | 20 | 1 |
| Total liabilities | 34 | 48 | 103 | 43 |
| -30 | -45 | -97 | 79 | |
| 1 | 1 | 19 | 15 | |
| – | – | – | -41.3% | |
| 51.2% | 32.7% | 71.6% | -55.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -10 | -14 | -21 | -38 | |
| – | – | – | 0 | |
| -10 | -14 | -21 | -39 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 1 | 2 |
Valuation
- –
- –
- –
- 1.5×
- –
- –
- 0.1×
- -115.2%
- -115.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -41.1%
- -16.7%
- -73.1%
- -35.7%
- -41.2%
- –
Growth
- –
- –
- +36.2%
- –
- +53.8%
Financial health
- 2.3×
- 0.02
- 1.2%
- -32.0×
- 12.23
- 12.23
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 10%of 952
Bottom 20%of 884
What analysts expect
- Average price target
- $18.67
- Range
- $14.00 – $23.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.46 | -0.52 | +11.5% |
| Mar 17, 2026 | -0.44 | -0.56 | +21.4% |
| Nov 12, 2025 | -0.64 | -0.66 | +3.0% |
| Aug 13, 2025 | -0.61 | -0.51 | −19.6% |
| May 14, 2025 | -2.52 | -0.78 | −223.1% |
| Mar 7, 2025 | -3.64 | -2.76 | −31.8% |
| Nov 12, 2024 | -0.04 | -0.14 | +71.4% |
| Jun 30, 2024 | -1.13 | -2.37 | +52.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
65Pass
Philip Fisher
32No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
25No pass
Terry Smith
25No pass
Questions about Kalaris Therapeutics
Is Kalaris Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kalaris Therapeutics AI analysis
What does Kalaris Therapeutics do?
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. It is in Biotechnology.
Does Kalaris Therapeutics pay a dividend?
No. Kalaris Therapeutics does not pay a dividend at the moment.
Is Kalaris Therapeutics stock halal?
No. Kalaris Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 262% of its market value, at or above the 33% limit. How we check
How has Kalaris Therapeutics stock done over the past year?
Down 70.5% over the past twelve months, to $1.58. It traded between $1.58 and $10.98 and is 85.7% below its high.
Who are Kalaris Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Kalaris Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.